DEVERRA THERAPEUTICS
OperatingDeverra Therapeutics, Inc.
Biotech · Biotech · Seattle, WA · Founded 2020
Biotech company committed to providing universal donor treatments
Financials
FY2021–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Share counts as of Dec 31, 2023| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Common Stock | 22,189,687 | — | 100.0% | $2.09Mar 2024 |
Principal holders% as the filing states it, May 6, 2026
- Dr. Colleen Delaney7,779,656 Common Stock29.9%of company
- Visavor5,972,703 Common Stock24.1%of company
- Michael Yurkowsky4,071,253 Common Stock16.2%of company
Sold to the crowd
- Reg CF · Mar 2024464,602 shares at $2.09$971K· 338 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
4 people
Dr. Colleen Delaney is Scientific Founder and Chief Scientific Officer, EVP of R&D at Deverra Therapeutics, a cellular therapy company focused on development of universal donor, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases. Dr. Delaney is an Attending Physician on the Stem Cell Transplant/Cell Therapy Service at the University of Washington/Seattle Children's Hospital. In addition, she is an Affiliate and former Professor of the Fred Hutchinson Cancer Center where she was PI of an NIH/government funded laboratory and where she established and became the Director of the Program in Cord Blood Transplant and Cord Blood Research. Dr. Delaney’s research interests focus on the development of methods to expand the number of umbilical cord blood stem cells and to then direct these cells to further differentiate into mature blood and immune cells for clinical application. She has more than 20 years of experience in all areas of development of cord blood derived allogeneic cell therapies from bench to bedside, including pre-clinical and IND-enabling research, investigator/sponsor of multiple INDs, regulatory oversight, and clinical trial design and principal investigator of multiple clinical trials. She isan inventor on numerous patents. Dr. Delaney received her MSc from Oxford University and her MD from Harvard Medical School and is the recipient of numerous awards, including the prestigious Damon Runyon Foundation Award, the Dr. Ali Al-Johani Award in recognition of exemplary clinical medical care and compassion to patients and families, the Seattle Business Journal’s Leaders in Health Care Award for Outstanding Medical Research, the Seattle American Women in Science’s Award for the Scientific Advancement and Leadership in STEM and she is a 2019 Inductee into the Washington Life Science Hall of Fame.
Michael brings more than 30 years of experience in financial services, initially as a broker with several national broker-dealers and as an investment banker. From 2003 to 2010 Michael founded and managed a hedge fund focused on debt arbitrage. Throughout his career, Michael has served on multiple public and private boards and has been involved in several M&A transactions. Michael currently serves as the CEO of Innoveren Scientific, a public life sciences company focused on regenerative medicine. Michael currently runs his own Family Office, which focuses on making investments in the Life Science industry.
Andrew “Al” Kucharchuk is a finance executive who has served in C-suite positions of multiple microcap companies since 2012. He has a proven ability to increase the overall financial health of a company by reducing costs, improving internal controls and overall efficiency management. Al is proficient in tax and regulatory compliance, budgeting and forecasting, internal controls, auditing, corporate strategy, SEC filings, financial analysis, and equity and debt financing. Currently, he serves as the Chief Financial Officer of Theralink Technologies, Inc as well as the Chief Operating Officer of Adhera Therapeutics, Inc. Mr. Kucharchuk received his bachelor’s degree from Louisiana State University and his MBA with a finance concentration from Tulane University.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 3 of 3 annual reports (FY2023–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 9 filings on EDGAR- Form C-ARMay 6, 20260001822782-26-000003EDGAR
- Form C-ARApr 10, 20250001665160-25-000587EDGAR
- Form C-USep 25, 20240001665160-24-001345EDGAR
- Form C/AJun 12, 20240001665160-24-000977EDGAR
- Form C/AApr 26, 20240001665160-24-000559EDGAR
- Form C-ARApr 26, 20240001665160-24-000561EDGAR
- Form CMar 28, 20240001665160-24-000283EDGAR
- Form DSep 18, 20230001822782-23-000003EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.